Why the study?
The prevalence of hyperlipidemia is rising among Iranian children and adolescents, yet no national guideline existed for its diagnosis, management, and treatment.
Establishes the first national, evidence-based clinical practice guidelines for the diagnosis, risk-stratified management, and pharmacological treatment of pediatric hyperlipidemia in Iran.
Answers are grounded in this paper and cite their sources.
Offers first national framework for Iranian pediatric hyperlipidemia; leaves open need for prospective validation before practice change.
Background: The prevalence of hyperlipidemia is rising among Iranian children and adolescents, yet no national guideline exists for its diagnosis, management, and treatment. To address this gap, the Iranian Ministry of Health commissioned the development of the first national guideline for pediatric hyperlipidemia. Materials and Methods: The guideline development group formulated recommendations to address six key clinical questions, grounded in a comprehensive review of current scientific evidence. Results: For children and adolescents with elevated low-density lipoprotein cholesterol (LDL-C) but no additional risk factors, the threshold for initiating pharmacological therapy was set at LDL-C ≥190 mg/dl. It was recommended to perform fasting lipid profile tests and alanine aminotransferase and creatine kinase tests before treatment initiation and again 4 weeks after treatment onset for follow-up. Lifestyle modification was considered as the first therapeutic intervention, and pharmacological therapy was recommended if LDL-C and triglyceride (TG) levels have not reached the therapeutic goal within at least six months from the initiation of lifestyle modification interventions. Statins were recommended as the first-line treatment in children over 10 years of age along with lifestyle modification; moreover, fibrate treatment was suggested in patients with high TG. The LDL-C therapeutic goal in children and adolescents with increased LDL-C without comorbidities and risk factors, as well as in those at medium risk, was considered to be <130 mg/dl, and in children and adolescents at high risk, it was considered to be <100 mg/dl. Furthermore, the TG therapeutic goal in children and adolescents with increased TG who do not have comorbidities and risk factors was considered to be <200 mg/dl. Conclusion: This guideline suggests evidence-based, context-specific recommendations for diagnosing, managing, and treating hyperlipidemia in Iranian children and adolescents, with emphasis on risk-stratified treatment thresholds, lifestyle modification, and pharmacological therapy. It is intended for pediatricians, general practitioners, cardiologists, and other healthcare providers in Iran.
No takes yet. Share an insight, caveat, or question.
Sarrafzadegan et al. (2026) studied Pediatric hyperlipidemia. Lifestyle modification and pharmacological therapy (statins as first-line for children >10 years, fibrates for high TG) was evaluated on Therapeutic lipid goals (LDL-C <130 mg/dl for low/medium risk, LDL-C <100 mg/dl for high risk, and TG <200 mg/dl without comorbidities).
Synapse has enriched 10 related papers. Consider them for comparative context: